Case report: Complete response of a bladder cancer patient with multiple hepatic and pelvic metastases treated by nab-paclitaxel combined with sintilimab

被引：2

作者：

Tao, Zhu-lei ^{[1
,2
]}

Wu, Wei ^{[3
]}

Liang, Lin-chun ^{[3
]}

Pan, Jin-feng ^{[1
,2
]}

Cao, Jian-zhou ^{[1
,2
]}

Jia, Xiao-long ^{[4
,5
]}

Fang, Li ^{[4
,5
]}

Ma, Qi ^{[2
,5
,6
,7
]}

机构：

[1] Ningbo Univ, Med Sch, Ningbo, Zhejiang, Peoples R China

[2] Affiliated Hosp Ningbo Univ, Ningbo Hosp 1, Comprehens Genitourinary Canc Ctr, Ningbo, Zhejiang, Peoples R China

[3] Mingzhou Hosp, Dept Med Oncol, Ningbo, Zhejian, Peoples R China

[4] Affiliated Hosp Ningbo Univ, Ningbo Hosp 1, Dept Urol, Ningbo, Zhejiang, Peoples R China

[5] Ningbo Clin Res Ctr Urol Dis, Ningbo, Zhejiang, Peoples R China

[6] Translat Res Lab Urol, Ningbo, Zhejiang, Peoples R China

[7] Yi Huan Genitourinary Canc Grp, Ningbo, Zhejiang, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

case report; nab-paclitaxel; PD-1; metastatic bladder cancer; sintilimab; CISPLATIN-INELIGIBLE PATIENTS; UROTHELIAL CARCINOMA; SINGLE-ARM; OPEN-LABEL; MULTICENTER; PEMBROLIZUMAB; CHEMOTHERAPY; THERAPY; ATEZOLIZUMAB;

D O I：

10.3389/fonc.2022.1020793

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This article described a patient with metastatic bladder cancer (mBC) who was successfully treated with nab-paclitaxel plus sintilimab. Localized muscle-invasive bladder cancer (MIBC) was discovered in a 56-year-old man who received radical cystectomy and platinum-based adjuvant chemotherapy. Eleven months after cystectomy, this patient developed numerous hepatic and pelvic metastases and progressed to mBC. The patient was given an anti-PD-1 antibody (sintilimab 200mg, q3w) in combination with Nab-paclitaxel (100mg, qw) for mBC. Complete remission (CR) was achieved after nine cycles of therapy, and the patient had no severe side effects during the treatment. The disease remained in CR after 41 months of follow-up. This case suggests that nab-paclitaxel combined with sintilimab is a safe and effective option in treatment of mBC.

引用

页数：5

共 25 条

[1] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[5] Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation [J].

Cao, Jian-zhou ;

Wu, Wei ;

Pan, Jin-feng ;

Wang, Hong-wei ;

Jiang, Jun-hui ;

Ma, Qi .

FRONTIERS IN ONCOLOGY, 2021, 11

[6] The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma [J].

Cathomas, Richard ;

Lorch, Anja ;

Bruins, Harman M. ;

Comperat, Eva M. ;

Cowan, Nigel C. ;

Efstathiou, Jason A. ;

Fietkau, Rainer ;

Gakis, Georgios ;

Hernandez, Virginia ;

Espinos, Estefania Linares ;

Neuzillet, Yann ;

Ribal, Maria J. ;

Rouanne, Matthieu ;

Thalmann, George N. ;

van der Heijden, Antoine G. ;

Veskimae, Erik ;

Witjes, J. Alfred ;

Milowsky, Matthew I. .

EUROPEAN UROLOGY, 2022, 81 (01) :95-103

[7] Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience [J].

Crist, Michael ;

Iyer, Gopa ;

Hsu, Miles ;

Huang, William C. ;

Balar, Arjun, V .

THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11 :1-9

[8] The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies [J].

Emens, Leisha A. ;

Middleton, Gary .

CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) :436-443

[9]

fda, FDA BRIEF FDA ONCOLO

[10] Bladder Cancer. Version 3.2020 [J].

Flaig, Thomas W. ;

Spiess, Philippe E. ;

Agarwal, Neeraj ;

Bangs, Rick ;

Boorjian, Stephen A. ;

Buyyounouski, Mark K. ;

Chang, Sam ;

Downs, Tracy M. ;

Efstathiou, Jason A. ;

Friedlander, Terence ;

Greenberg, Richard E. ;

Guru, Khurshid A. ;

Guzzo, Thomas ;

Herr, Harry W. ;

Hoffman-Censits, Jean ;

Hoimes, Christopher ;

Inman, Brant A. ;

Jimbo, Masahito ;

Kader, A. Karim ;

Lele, Subodh M. ;

Michalski, Jeff ;

Montgomery, Jeffrey S. ;

Nandagopal, Lakshminarayanan ;

Pagliaro, Lance C. ;

Pal, Sumanta K. ;

Patterson, Anthony ;

Plimack, Elizabeth R. ;

Pohar, Kamal S. ;

Preston, Mark A. ;

Sexton, Wade J. ;

Siefker-Radtke, Arlene O. ;

Tward, Jonathan ;

Wright, Jonathan L. ;

Gurski, Lisa A. ;

Johnson-Chilla, Alyse .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (03) :329-354

← 1 2 3 →